Real-world studies have become increasingly important in providing evidence of treatment
effectiveness in clinical practice. While randomized clinical trials (RCTs) are the “gold …

Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability
of numerous glucose‐lowering therapies and clear guidelines for T2D management …

People with type 2 diabetes form a heterogeneous group. Consequently, treatment
regimens and therapeutic targets should be individualized. The treatment of type 2 diabetes …

OBJECTIVE To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-
300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥ …

OBJECTIVE The epidemic of type 2 diabetes (T2DM) threatens to become the major public
health problem of this century. However, a comprehensive comparison of the long-term …

Optimal glycemic control is fundamental to the management of diabetes. Regardless of the
underlying treatment, glycated hemoglobin (A1C) levels> 7.0% are associated with a …

Key Clinical Points Glycemic Control in Type 2 Diabetes Mellitus Intensive glycemic control
reduces the risk of microvascular complications of type 2 diabetes, but the effect of strict …

OBJECTIVE To determine the relative contributions of basal hyperglycemia (BHG) versus
postprandial hyperglycemia (PPHG) before and after treatment intensification in patients …

Background The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the UK and
worldwide. Before the onset of T2DM, there are two conditions characterised by blood …

Exenatide, the gliptins and detemir were all clinically effective. The long-acting insulin
analogues glargine and detemir appeared to have only slight clinical advantages over NPH …